Treatment with a GPIIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients

Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fost...

Full description

Saved in:
Bibliographic Details
Published inThrombosis and haemostasis Vol. 80; no. 3; p. 370
Main Authors Keularts, I M, Béguin, S, de Zwaan, C, Hemker, H C
Format Journal Article
LanguageEnglish
Published Germany 01.09.1998
Subjects
Angina, Unstable - blood
Angina, Unstable - drug therapy
Heparin - pharmacology
Heparin - therapeutic use
Humans
Injections, Intravenous
Myocardial Infarction - blood
Myocardial Infarction - drug therapy
Platelet Aggregation Inhibitors - pharmacology
Platelet Aggregation Inhibitors - therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Thrombin - antagonists & inhibitors
Thrombin - biosynthesis
Tyrosine - analogs & derivatives
Tyrosine - pharmacology
Tyrosine - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Infusion of the GPIIb/IIIa-inhibitor MK383 inhibits thrombin generation in platelet rich plasma by interfering with the production of platelet procoagulant phospholipid exposure. The effect is similar to that of 0.2 U/ml of heparin. Heparin infusion, well known to inhibit thrombin generation by fostering antithrombin activity, inhibits the formation of platelet-derived procoagulant microparticles, probably by decreasing the formation of free thrombin, which, under our circumstances, is the main platelet activator.
ISSN:0340-6245
DOI:10.1055/s-0037-1615213